InsiderTrades.com logo
Dems have chosen Biden replacement?
From Paradigm Press   |   Ad
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
See who it is HERE.

QNCX Insider Trading

Insider Ownership Percentage: 21.00%
Insider Buying (Last 12 Months): $648,111.20
Insider Selling (Last 12 Months): $0.00

Quince Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Quince Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Quince Therapeutics Share Price & Price History

Current Price: $0.99
Price Change: ▲ Price Increase of +0.03 (3.14%)
As of 05/3/2024 01:00 AM ET

This chart shows the closing price history over time for QNCX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Global crypto currency reset (41 major banks signed up)
From Stansberry Research   |   Ad
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
 Here's everything you need to know.

Quince Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2023David LamondDirectorBuy22,627$1.04$23,532.082,347,545View SEC Filing Icon  
12/12/2023David LamondDirectorBuy22,327$1.02$22,773.542,302,291View SEC Filing Icon  
12/7/2023David LamondDirectorBuy19,123$1.01$19,314.232,279,664View SEC Filing Icon  
12/5/2023David LamondDirectorBuy19,123$1.01$19,314.232,241,418View SEC Filing Icon  
12/1/2023David LamondDirectorBuy14,378$0.94$13,515.322,222,295View SEC Filing Icon  
11/29/2023David LamondDirectorBuy14,378$0.98$14,090.442,193,539View SEC Filing Icon  
8/30/2023David LamondDirectorBuy41,026$1.31$53,744.062,138,135View SEC Filing Icon  
8/17/2023David LamondDirectorBuy24,766$1.29$31,948.142,097,109View SEC Filing Icon  
8/15/2023David LamondDirectorBuy107,886$1.32$142,409.521,954,995View SEC Filing Icon  
8/10/2023Dirk ThyeCEOBuy88,000$1.26$110,880.00448,911View SEC Filing Icon  
8/8/2023Brendan HannahInsiderBuy71,762$1.22$87,549.64201,555View SEC Filing Icon  
8/8/2023Dirk ThyeCEOBuy80,000$1.24$99,200.00360,911View SEC Filing Icon  
8/8/2023Margaret McloughlinDirectorBuy8,000$1.23$9,840.008,000View SEC Filing Icon  
3/6/2023Ted MonohonCAOSell1,871$0.98$1,833.5827,440View SEC Filing Icon  
See Full Table
The asset beating inflation by 4x
From Colonial Metals   |   Ad
"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.
That's why we have released our Free Precious Metals Investment Guide that explains all the details

SEC Filings (Institutional Ownership Changes) for Quince Therapeutics (NASDAQ:QNCX)

30.75% of Quince Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at QNCX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Quince Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
1/12/2024Scharf Investments LLC91,061$96K0.0%N/A0.212%Search for SEC Filing on Google Icon
7/31/2023Intellectus Partners LLC53,527$81K0.0%N/A0.148%Search for SEC Filing on Google Icon
7/24/2023BML Capital Management LLC1,411,839$2.13M1.9%N/A3.892%Search for SEC Filing on Google Icon
5/11/2023EPIQ Capital Group LLC958,469$1.50M0.8%-9.3%2.642%Search for SEC Filing on Google Icon
4/20/2023Hennion & Walsh Asset Management Inc.31,061$48K0.0%N/A0.086%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Quince Therapeutics logo
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More on Quince Therapeutics

Today's Range

Now: $0.99
Low: $0.92
High: $0.99

50 Day Range

MA: $1.12
Low: $0.94
High: $1.34

52 Week Range

Now: $0.99
Low: $0.84
High: $1.74

Volume

49,206 shs

Average Volume

76,586 shs

Market Capitalization

$42.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Who are the company insiders with the largest holdings of Quince Therapeutics?

Quince Therapeutics' top insider shareholders include:
  1. David Lamond (Director)
  2. Dirk Thye (CEO)
  3. Brendan Hannah (Insider)
  4. Ted Monohon (CAO)
  5. Margaret Mcloughlin (Director)
Learn More about top insider investors at Quince Therapeutics.
Dems have chosen Biden replacement?
From Paradigm Press   |   Ad
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
See who it is HERE.